August 04, 2016 09:09 ET OCLS Keeping in Step With Innovation and US Dermatology Market Penetration

REDONDO BEACH, CA--(Marketwired - Aug 4, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, announces publication of an article examining Oculus Innovative Sciences' (NASDAQ: OCLS) steadily improving performance in the U.S. dermatology market and what that means for the company moving forward.

Shares of Oculus Innovative Sciences (NASDAQ: OCLS) are often volatile around earnings time and this time the reaction was to the downside, even though the company delivered on its guidance from the prior earnings report. More importantly, the company is methodically executing on its business model, underscored by four cornerstones of growth: growing its current U.S. dermatology products, introduction of new products, gentle price increases and building a larger domestic sales force.

In the U.S., product revenues improved 74% from the year earlier quarter to $1.4 million. This was the first full quarter for sales of Oculus' skin repair product Ceramax, which is expected to transition into the company's top selling product. Launched at the end of March, 1,084 Ceramax prescriptions were filled last quarter at an average wholesale acquisition price of $214, marking the best and fastest sales ramp for a company product ever. By all counts from Symphony monthly data, Oculus continues to penetrate the U.S. derm market as it planned. 

To read the full article on, please click the link or copy and paste the URL into your browser:


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information